Race-specific drugs: regulatory trends and public policy
By David E. Winickoff and Osagie K. Obasogie,
Trends in Pharmacological Sciences
| 06. 04. 2008
Numerous articles and commentaries in the health literature recently have questioned the emergence of race as an increasingly powerful organizing principle in clinical medicine and pharmaceutical development [1,2]. Yet proposals for regulatory reform remain thin. Debate over racebased medicine crystallized around the FDA's June 2005 approval of BiDil, a drug approved to treat African-Americans with heart failure. Some saw BiDil as a dangerous example of marketing trumping science [3], whereas others heralded BiDil as a step towards eliminating racial disparities in health care [4]. One thing is clear: the BiDil debate has left major questions about how clinical trial design and drug regulation should engage this trend [5].
The need for new regulatory approaches to medicines with race-specific indications is growing more acute. A new trend towards designing and conducting clinical trials for race-specific medicines [6] carries serious implications for equitable access to pharmaceutical innovations. Under current policies FDA-approved racial indications might prevent certain groups from accessing certain drugs, even when there is little evidence to warrant such exclusion. Given the stakes of such exclusions for public health, new regulatory...
Related Articles
By Emma McDonald Kennedy
| 09.25.2025
In the leadup to the 2024 election, Donald Trump repeatedly promised to make IVF more accessible. He made the commitment central to his campaign, even referring to himself as the “father of IVF.” In his first month in office, Trump issued an executive order promising to expand IVF access. The order set a 90-day deadline for policy recommendations for “lowering costs and reducing barriers to IVF,” although it didn’t make any substantive reproductive healthcare policy changes.
The response to the...
By Margaux MacColl, The San Francisco Standard | 09.17.2025
Designer babies are coming soon to an IVF clinic near you.
Nucleus Genomics, founded by Kian Sadeghi in 2020, when he was just 20, got its start analyzing genomes to weigh a person’s risk of everything from cancer to ADHD...
By Marianne Lamers, NEMO Kennislink [cites CGS' Katie Hasson] | 09.23.2025
Een rijtje gespreide vulva’s gaapt de bezoeker aan. Zó ziet een bevalling eruit, en zó een baarmoeder met foetus. Een zwangerschap, maar dan zonder zwangere vrouw, gestript van zorgen, gêne en pijn. De zwangerschapsmodellen en oefenbekkens, te zien in de...
By Charmayne Allison, ABC News | 09.21.2025
It has been seven years since Chinese biophysicist He Jiankui made an announcement that shocked the world's scientists.
He had made the world's first gene-edited babies.
Through rewriting DNA in twin girls' embryos, the man who would later be dubbed...